April 22, 2023

Martin-Immanuel Bittner 𝘔𝘋 𝘋𝘗𝘩𝘪𝘭 𝘍𝘙𝘚𝘈 CEO & Co-Founder of Arctoris

In this episode of the Life Science Success podcast, my guest is Martin-Immanuel Bittner 𝘔𝘋 𝘋𝘗𝘩𝘪𝘭 𝘍𝘙𝘚𝘈. Martin-Immanuel is the CEO & Co-Founder of Arctoris, a biotech platform company powered by robotics and machine...

Show Notes
Guest Profile

Martin-Immanuel Bittner is the CEO and founder of Arctoris, a biotech platform company focused on drug discovery with partnerships worldwide.

Martin-Immanuel Bittner is the CEO and founder of Arctoris, a biotech platform company powered by robotics and machine learning based in Oxford and Boston
The company's focus is on drug discovery, and it has partnerships with dozens of biotech and pharma companies worldwide
The company is actively hiring and anticipates continued revenue growth and team growth in the coming years
Bittner is excited about the continued drive towards having physiologically more relevant model systems
Bittner sees AI and machine learning as powerful tools that will be increasingly adopted in a drug discovery context and predicts that all drugs reaching the market will have had some form of AI involvement in the future
Bittner is concerned about human health being jeopardized by conflicts between different geopolitical blocks and the risk management that companies need to consider
Bittner is excited about the transformation of the industry and the opportunities that lie ahead with new technologies and techniques that can bring more and better drugs to patients faster

Please check out our Life Science Success Resources. You will find tools that will support growing companies and books for authors I have interviewed.

Martin-Immanuel Bittner

CEO

Martin-Immanuel Bittner MD DPhil FRSA FRSB FIBMS is the Chief Executive Officer of Arctoris, a biotech company combining automated wet lab operations and machine learning for accelerated small molecule discovery. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford, where he co-founded Arctoris. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organizations, including EACR, AACR, and ESTRO. Martin is an elected member of the Young Academy of the German National Academy of Sciences and of Sigma Xi, and has been named Innovator of the Year in Biotechnology 2020 by SBR.